Subscribe
brexit-istock-537519806_andrewlinscott
andrewlinscott / iStockphoto.com
16 November 2018Big Pharma

Brexit draft deal: a welcome step but more certainty needed, say lawyers

While the pharmaceutical industry has welcomed the draft Withdrawal Agreement for the UK’s departure from the EU, more clarity is still needed, lawyers have told LSIPR.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
UK life sciences bodies submit concerns over ‘no deal’ Brexit
12 November 2018   Associations representing the pharmaceutical and biotechnology fields have said that the UK should maintain “close cooperation” with the EU post-Brexit, to ensure that access to safe and effective medicines continues in both markets.
Big Pharma
Pharma organisations underline Brexit concerns in letter to negotiators
19 July 2017   The Association of the British Pharmaceutical Industry and seven other UK and European life sciences bodies have jointly written to the UK and EU Brexit negotiators.


Editor's picks

‘We created law’: G1/24 and the creation of the ‘diamond standard’
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025

Editor's picks

Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

More on this story

Big Pharma
UK life sciences bodies submit concerns over ‘no deal’ Brexit
12 November 2018   Associations representing the pharmaceutical and biotechnology fields have said that the UK should maintain “close cooperation” with the EU post-Brexit, to ensure that access to safe and effective medicines continues in both markets.
Big Pharma
Pharma organisations underline Brexit concerns in letter to negotiators
19 July 2017   The Association of the British Pharmaceutical Industry and seven other UK and European life sciences bodies have jointly written to the UK and EU Brexit negotiators.

More on this story

Big Pharma
UK life sciences bodies submit concerns over ‘no deal’ Brexit
12 November 2018   Associations representing the pharmaceutical and biotechnology fields have said that the UK should maintain “close cooperation” with the EU post-Brexit, to ensure that access to safe and effective medicines continues in both markets.
Big Pharma
Pharma organisations underline Brexit concerns in letter to negotiators
19 July 2017   The Association of the British Pharmaceutical Industry and seven other UK and European life sciences bodies have jointly written to the UK and EU Brexit negotiators.

More features

‘We created law’: G1/24 and the creation of the ‘diamond standard’
BMS unit loses cell therapy patent at European Patent Office
Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market
Lord Justice Birss to become chancellor of the High Court
Bankruptcy judge approves $305m sale of genetics testing company
Sanofi successfully challenges rare disease patent in Europe
Bayer appoints new head of IP
WATCH: Policy direction—where are we now?